MINK THERAPEUTICS INC
NASDAQ: INKT (MiNK Therapeutics, Inc.)
Kemas kini terakhir: 2 hari lalu, 4:44PM8.02
-0.59 (-6.85%)
| Penutupan Terdahulu | 8.61 |
| Jumlah Dagangan | 18,935 |
| Purata Dagangan (3B) | 15,631 |
| Modal Pasaran | 41,171,836 |
| Harga / Jualan (P/S) | 218.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2026 |
| Margin Operasi (TTM) | -5,720.70% |
| EPS Cair (TTM) | -2.23 |
| Nisbah Semasa (MRQ) | 0.970 |
| Aliran Tunai Operasi (OCF TTM) | -7.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.21 M |
| Pulangan Atas Aset (ROA TTM) | -61.63% |
Sentimen Berita
-
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
11 Nov, 6:30AM
-
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
11 Nov, 4:12PM
-
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
11 Nov, 3:06PM
AISkor Stockmoo
| Nilai 30% | -4.6 |
| Keuntungan lemah. Kecairan jangka pendek nipis. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Pulangan atas Modal info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -3.2 |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.8 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 0.1 |
| Institusi bersih -0.08% daripada saham dalam pemfailan 13F terkini: 7 pemegang menambah, 10 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -15.2% dari 31 Aug hingga 30 Oct 2026, 4.3 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham meningkat setiap tahun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Tiada isyarat jelas daripada sokongan dan rintangan. info | |
| Skor Akhir | -2.89 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | MiNK Therapeutics, Inc. | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| INKT | 41 M | - | - | - | -2.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
|
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 59.34% |
| % Dimiliki oleh Institusi | 3.79% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Longbow Finance Sa | 30 Sep 2026 | 16,667 |
| Paladin Partners, Llc | 30 Sep 2026 | 500 |
| Covestor Ltd | 30 Sep 2026 | 119 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 5.11%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 7 | 42,714 |
| Berkurang | 10 | 31,208 |
| Baharu | 1 | 72 |
| Dijual habis | 4 | 15,468 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 55,094 | 4.3 |
| 15 Oct 2026 | 47,778 | 2.4 |
| 30 Sep 2026 | 49,583 | 3.1 |
| 15 Sep 2026 | 57,136 | 3.1 |
| 31 Aug 2026 | 64,965 | 6.8 |
| 14 Aug 2026 | 78,320 | 9.0 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
First revenue lands as the ARDS trial enters randomized Phase II. |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of MiNK Therapeutics, Inc.'s Q3 2026 earnings call… |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
MiNK Therapeutics Inc (INKT) pairs durable oncology survival data with a newly initiated randomized ARDS program, all while maintaining a disciplined cash runway of at least 12 months. |
| 11 Nov 2026 | Yahoo Finance |
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with preliminary findings expected in the second half of 2026, executives said on the company’s first-quarter ear… |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
MiNK Therapeutics, Inc. (INKT) delivered earnings and revenue surprises of +24.24% and +33.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living… |
| 06 Nov 2026 | Yahoo Finance |
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale for an ongoing Phase 2 combination studySenolytic activity: agenT-797 and… |
| 02 Nov 2026 | Yahoo Finance |
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual MeetingNEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE)… |
| 02 Oct 2026 | Yahoo Finance |
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW… |
| 30 Sep 2026 | Yahoo Finance |
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand… |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |